Ching-Chi Lee1, Chung-Hsun Lee2, Ming-Yuan Hong2, Chih-Chia Hsieh3, Hung-Jen Tang4, Wen-Chien Ko5. 1. Division of Critical Care Medicine, Department of Internal Medicine, Madou Sin-Lau Hospital, Tainan 72152, Taiwan; Graduate Institute of Medical Sciences, College of Health Sciences, Chang Jung Christian University, Tainan 71101, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan. 2. Department of Medicine, National Cheng Kung University Medical College, Tainan 70403, Taiwan; Department of Emergency Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan. 3. Department of Emergency Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan. 4. Department of Medicine, Chi-Mei Medical Center, Tainan 71004, Taiwan; Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan. Electronic address: 8409d1@gmail.com. 5. Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 70403, Taiwan; Department of Medicine, National Cheng Kung University Medical College, Tainan 70403, Taiwan. Electronic address: winston3415@gmail.com.
Abstract
BACKGROUND: The presence of extended-spectrum β-lactamase (ESBL) in Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) is of great microbiological and clinical importance. The study dealing with the direct impact of ESBL producers on the outcome of patients with community-onset bacteremia is lacking. METHODS: Adults with community-onset EKP bacteremia were recruited retrospectively during a 6-year period. ESBL producers were determined according to ESBL phenotype. ESBL patients were compared on a 1:2 basis with non-ESBL patients by using propensity-score matching (PSM) calculated based on independent predictors of 28-day mortality. RESULTS: Of the 1141 eligible adult patients, 65 (5.7%) caused by ESBL producers. Significant differences between the two groups were discovered in the proportions of patients with critical illness (a Pitt bacteremia score ≥ 4) at bacteremia onset, inappropriate empirical antibiotic therapy, bacteremia because of urosepsis and pneumonia, and several comorbidities. In a PSM analysis after controlling for six independent predictors-critical illness at bacteremia onset, underlying fatal comorbidities (McCabe classification), inappropriate empirical antibiotic therapy, comorbidities with liver cirrhosis, bacteremia because of urosepsis and pneumonia-a appropriate matching between two groups (ESBL group, 60 patients; non-ESBL group, 120) were observed in age, causative microorganism, bacteremia severity, major comorbidities, comorbidity severity, and major bacteremia source. Consequently, a strong relationship between ESBL producers and poor prognosis was highlighted. CONCLUSIONS: The adverse influence of ESBL producers on clinical outcomes was presented with respect to adults with community-onset EKP bacteremia. Establishing a predictive scoring algorithm for identifying patients at risk of ESBL-producer infections is crucial.
BACKGROUND: The presence of extended-spectrum β-lactamase (ESBL) in Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) is of great microbiological and clinical importance. The study dealing with the direct impact of ESBL producers on the outcome of patients with community-onset bacteremia is lacking. METHODS: Adults with community-onset EKP bacteremia were recruited retrospectively during a 6-year period. ESBL producers were determined according to ESBL phenotype. ESBLpatients were compared on a 1:2 basis with non-ESBLpatients by using propensity-score matching (PSM) calculated based on independent predictors of 28-day mortality. RESULTS: Of the 1141 eligible adult patients, 65 (5.7%) caused by ESBL producers. Significant differences between the two groups were discovered in the proportions of patients with critical illness (a Pitt bacteremia score ≥ 4) at bacteremia onset, inappropriate empirical antibiotic therapy, bacteremia because of urosepsis and pneumonia, and several comorbidities. In a PSM analysis after controlling for six independent predictors-critical illness at bacteremia onset, underlying fatal comorbidities (McCabe classification), inappropriate empirical antibiotic therapy, comorbidities with liver cirrhosis, bacteremia because of urosepsis and pneumonia-a appropriate matching between two groups (ESBL group, 60 patients; non-ESBL group, 120) were observed in age, causative microorganism, bacteremia severity, major comorbidities, comorbidity severity, and major bacteremia source. Consequently, a strong relationship between ESBL producers and poor prognosis was highlighted. CONCLUSIONS: The adverse influence of ESBL producers on clinical outcomes was presented with respect to adults with community-onset EKP bacteremia. Establishing a predictive scoring algorithm for identifying patients at risk of ESBL-producer infections is crucial.
Authors: Miriam Moscoso; Juan A Vallejo; Maria P Cabral; Patricia García; Víctor Fuentes-Valverde; Eva Gato; Jorge Arca-Suárez; Pablo Aja-Macaya; Germán Bou Journal: Vaccines (Basel) Date: 2022-06-16